Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

Age-dependent efficacy of Bifidobacterium strains on cognitive impairment and dementia: A systematic review and meta-analysis.

  • 2025-09
  • Ageing research reviews 111
    • Wenliang Yu
    • Yao Li
    • Zeyang Liu
    • Siqi Hua
    • Ziyi Tan
    • Wei Tang
    • Mengyue Gao
    • Xiaoran Zhou
    • Zichun Hua

Study Design

Type
Meta-Analysis
Sample size
n = 1,195
Population
patients with cognitive impairment and dementia
Methods
Systematic searches across Embase, PubMed, Medline, Wanfang, and ClinicalTrials.gov; risk of bias assessed using NOS; registered with PROSPERO (CRD42023460809)

Objective

Cognitive impairment and dementia are prevalent and costly diseases, affecting 5-8 % of individuals aged 60 and above globally. Bifidobacterium, a low-cost probiotic, has shown potential in treating dementia, but its efficacy remains controversial. To investigate the effects of Bifidobacterium on various dementia-related functional tests and biomarkers in different patient populations with cognitive impairment and dementia.

Methods

Systematic searches were conducted on February 15, 2025, across Embase, PubMed, Medline, Wanfang, and ClinicalTrials.gov. The risk of bias was assessed using NOS. The study is registered with PROSPERO (CRD42023460809).

Results

After rigorous screening, 18 studies encompassing 1195 patients were included. The results revealed that Bifidobacterium significantly improved cognitive function (MMSE, WMD = 2.26, 95 % CI = 1.69-2.83, compared to placebo: p = 0.049), particularly in patients under 70 (MMSE, WMD = 2.81, 95 % CI = 1.97-3.65). For patients over 70, better outcomes were achieved without B. breve-based treatments (MMSE, WMD = 2.43, 95 % CI = 1.76-3.09, compared to the group age under 70 or the group over 70 and receiving B. breve-based treatments: p = 0.0133). Additionally, Bifidobacterium significantly enhance patients' memory, language, visuospatial, attention and executive abilities, potentially through the downregulation of triglycerides (WMD = -19.52, 95 % CI = -32.28 to -6.66, p = 0.039) and MDA (SMD = -0.72, 95 % CI = -1.07 to -0.37, p = 0.0057).

Conclusions

These findings provide key insights into the efficacy of Bifidobacterium, supporting personalized treatment strategies and reducing the treatment burden for patients with cognitive impairment and dementia.

Research Insights

Back to top